tiprankstipranks
Trending News
More News >
Qiagen NV (CH:QGEN)
:QGEN
Switzerland Market
Advertisement

Qiagen (QGEN) Earnings Dates, Call Summary & Reports

Compare
0 Followers

Earnings Data

Report Date
Feb 10, 2026
After Close (Confirmed)
Period Ending
2025 (Q4)
Consensus EPS Forecast
0.49
Last Year’s EPS
0.49
Same Quarter Last Year
Moderate Buy
Based on 12 Analysts Ratings

Earnings Call Summary

Q3 2025
Earnings Call Date:Nov 04, 2025|
% Change Since:
|
Earnings Call Sentiment|Positive
QIAGEN demonstrated strong and consistent performance, with significant achievements in strategic initiatives, financial growth, and product segment performance. Despite challenges such as the U.S. government shutdown, headwinds from currency and tariffs, and regional sales declines, the company's positive trajectory and future growth plans contribute to an overall positive sentiment.
Company Guidance
In the third quarter of 2025, QIAGEN reported robust financial performance, with net sales rising 6% to $533 million and core sales growth of 6% at constant exchange rates (CER), excluding discontinued products. The company surpassed its earnings target, delivering an adjusted diluted EPS of $0.61 at both actual and CER, exceeding the outlook of at least $0.58. QIAGEN's adjusted operating income margin held steady at 29.6% of sales, despite facing headwinds from currency fluctuations and U.S. tariffs. The company remains committed to its 2028 ambitions, including a 7% sales CAGR from 2024 to 2028, and is on track to exceed its 31% adjusted operating income target by the end of 2028. Additionally, QIAGEN announced a $500 million synthetic share repurchase program to be completed by January 2026, aiming to surpass its $1 billion shareholder return goal by 2028. The acquisition of Parse Biosciences was highlighted as a strategic move to enhance QIAGEN's portfolio in the fast-growing AI-driven single-cell market.
Consistent Performance and Strategic Initiatives
QIAGEN delivered its 24th consecutive quarter meeting or exceeding targets, with a focus on high-growth areas of molecular research and testing. Key strategic initiatives include the acquisition of Parse Biosciences and a $500 million synthetic share repurchase.
Financial Metrics and Growth
Net sales rose 6% to $533 million, with core sales increasing 6% CER. Adjusted diluted EPS was $0.61, above the outlook of $0.58. The company raised its EPS target for 2025 by $0.10, reflecting strong performance.
Strong Product Segment Performance
QIAstat diagnostics and QuantiFERON both grew by 11% CER, while Sample technologies returned to growth with sales rising 3% CER. Digital PCR platform QIAcuity maintained double-digit CER growth.
Positive Cash Flow and Shareholder Returns
Operating cash flow was $466 million for the first nine months of 2025. A $500 million share repurchase is set for completion in January 2026, contributing to a total shareholder return goal of $1 billion by 2028.
Future Growth and Strategic Planning
QIAGEN is on track to achieve a 7% sales CAGR from 2024 to 2028, with ambitions to move well above a 31% adjusted operating income target by 2028.

Qiagen (CH:QGEN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

CH:QGEN Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Feb 10, 2026
2025 (Q4)
0.49 / -
0.493
Nov 04, 2025
2025 (Q3)
0.47 / 0.49
0.4744.10% (+0.02)
Aug 05, 2025
2025 (Q2)
0.49 / 0.49
0.4586.01% (+0.03)
May 07, 2025
2025 (Q1)
0.41 / 0.44
0.38316.28% (+0.06)
Feb 05, 2025
2024 (Q4)
0.50 / 0.49
0.4587.77% (+0.04)
Nov 06, 2024
2024 (Q3)
0.45 / 0.47
0.42910.57% (+0.05)
Jul 31, 2024
2024 (Q2)
0.43 / 0.46
0.4384.62% (+0.02)
Apr 29, 2024
2024 (Q1)
0.36 / 0.38
0.438-12.57% (-0.06)
Feb 06, 2024
2023 (Q4)
0.46 / 0.46
0.4550.71% (<+0.01)
Oct 30, 2023
2023 (Q3)
0.41 / 0.43
0.455-5.69% (-0.03)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

CH:QGEN Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 04, 2025
CHF50.36
Aug 05, 2025
CHF50.36CHF50.360.00%
May 07, 2025
CHF50.36CHF50.360.00%
Feb 05, 2025
CHF50.36CHF50.360.00%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Qiagen NV (CH:QGEN) report earnings?
Qiagen NV (CH:QGEN) is schdueled to report earning on Feb 10, 2026, After Close (Confirmed).
    What is Qiagen NV (CH:QGEN) earnings time?
    Qiagen NV (CH:QGEN) earnings time is at Feb 10, 2026, After Close (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is the P/E ratio of Qiagen NV stock?
          The P/E ratio of Qiagen is N/A.
            What is CH:QGEN EPS forecast?
            CH:QGEN EPS forecast for the fiscal quarter 2025 (Q4) is 0.49.
              What am I Missing?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis